Abstract 4455
Background
The TAILOR trial demonstrated a significant survival advantage with the addition of cetuximab to 1L FOLFOX-4 in patients from China with RAS wt mCRC and met all of its endpoints. We report the impact of primary tumor side on 3-year overall survival (OS) in TAILOR.
Methods
TAILOR was a randomized, open-label, multicenter, phase 3 trial that evaluated 1L cetuximab + FOLFOX-4 vs FOLFOX-4 in patients from China with RAS wt mCRC. The primary endpoint was progression-free survival time, as determined by independent review committee; secondary endpoints included OS time, ORR, and safety/tolerability. Tumors were categorized in evaluable patients as left (L)-sided (splenic flexure, descending colon, sigmoid colon, and rectum) or right (R)-sided (appendix, cecum, ascending colon, hepatic flexure, and transverse colon).
Results
Of the 393 treated patients with RAS wt mCRC, median follow-up time was 57.0 months (range, 1.5–75.5), and 391 patients were evaluable for tumor side. Median OS and 3-year OS rates by primary tumor side are summarized in the table.Table:
591P
Primary tumor side: L | Primary tumor side: R | |||
---|---|---|---|---|
Cetuximab + FOLFOX-4 (n = 146) | FOLFOX-4 (n = 162) | Cetuximab + FOLFOX-4 (n = 45) | FOLFOX-4 (n = 38) | |
Median OS (95% CI), months | 22.0 (18.7–25.5) | 18.3 (15.2–20.2) | 11.5 (7.5–20.4) | 9.4 (7.5–18.8) |
3-year OS rate (95% CI), % | 32 (25–40) | 16 (11–22) | 23 (11–38) | 14 (5–28) |
Conclusions
This updated analysis at > 4.5 years’ median follow-up is consistent with previous results from the TAILOR study, which showed improved OS with the addition of cetuximab to FOLFOX-4. Indeed, the 3-year OS rate was doubled in patients with L-sided mCRC and > 1.5 times higher in those with R-sided disease, showing that patients with mCRC might benefit from treatment with cetuximab irrespective of primary tumor side. Overall, these results confirm cetuximab in combination with FOLFOX-4 as an effective standard-of-care 1L therapy for patients with RAS wt mCRC.
Clinical trial identification
NCT01228734; EMR62202-057.
Editorial acknowledgement
Medical writing assistance (funded by Merck Healthcare KGaA, Darmstadt, Germany) was provided by Marjorie Rummelt, PhD, of ClinicalThinking, Inc, Hamilton, NJ, USA.
Legal entity responsible for the study
Merck Healthcare KGaA.
Funding
Merck Healthcare KGaA.
Disclosure
J. Nippgen: Full / Part-time employment: Merck Serono. W. Chen: Full / Part-time employment: Merck Serono. J. Li: Research grant / Funding (institution): Merck; Research grant / Funding (institution): Roche. All other authors have declared no conflicts of interest.
Resources from the same session
2840 - Effects of Aerobic and Resistance Exercise on Android:Gynoid Fat Ratio in Breast Cancer Survivors
Presenter: Christina Dieli-Conwright
Session: Poster Display session 2
Resources:
Abstract
869 - Impact of Education for Breast self examination in Rural Indian Women on Early Detection - results of POC study
Presenter: Sneha Parchuri
Session: Poster Display session 2
Resources:
Abstract
1951 - Breast cancer incidence and survival in renal transplant patients: 35-year experience
Presenter: Michalis Kontos
Session: Poster Display session 2
Resources:
Abstract
2017 - The changing landscape of breast cancer incidence after treatment for Hodgkin’s disease
Presenter: Amelia Benjamin
Session: Poster Display session 2
Resources:
Abstract
1780 - Number of deliveries as a prognostic factor in different breast cancer subtypes
Presenter: Anniina Jääskeläinen
Session: Poster Display session 2
Resources:
Abstract
4650 - Effects of supervised and adapted exercise program in the quality of life and strength of breast cancer survivors: MAMA MOVE Gaia trial
Presenter: Ana Joaquim
Session: Poster Display session 2
Resources:
Abstract
4962 - Study On the Socioeconomic and Clinical Factors Affecting the Proportion of Breast Conserving Surgery in Chinese Women Breast Cancer
Presenter: Jin Zhang
Session: Poster Display session 2
Resources:
Abstract
5451 - Clinical decision making and multidisciplinary team meetings (MDMs) in early breast cancer. Is the agreement between planned and applied therapeutic program?
Presenter: Marco Giavarra
Session: Poster Display session 2
Resources:
Abstract
888 - The value of genetic counselling in breast cancer genetic testing and clinical management
Presenter: Vicki Kiesel
Session: Poster Display session 2
Resources:
Abstract
4005 - Elderly patients in the Japanese Breast Cancer Registry
Presenter: Masataka Sawaki
Session: Poster Display session 2
Resources:
Abstract